Occlusion Device
Oct 08, 2026
Okami Medical Secures Expanded Indication for LOBO Vascular Occluder; CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and U.S. Patent for NeuroPASS™ 3; Danaher Accelerates Life Sciences Research with New AI-Powered Autonomous Lab; Aesthetic Brokers Advises SDBotox on Strategic Partnership; BD Advances Peripheral Vascular Innovation with Positive AGILITY Trial Results; Sonorous Neurovascular Secures FDA IDE Approval for Pivotal U.S. Trial of Venous Sinus Stent in Pulsatile Tinnitus
Okami Medical Received Expanded Indication for the LOBO Vascular Occluder On 07 October 2026, Okami Medical received an expanded FDA indication for its LOBO Vascular Occlusion System, extending the device's application from peripheral arterial procedures to peripheral venous embolization. The expanded indication...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
